Companies › KYNB
Kyntra Bio Inc (KYNB)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0000921299 · EDGAR filings · Updated 2026-06-17
Kyntra Bio Inc (KYNB) has reported institutional ownership of 25.6%, with 32 institutional managers holding positions valued at $7.01M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-06-17 — Insider transaction reported (Form 4)
- 2026-06-17 — Insider transaction reported (Form 4)
- 2026-06-17 — Insider transaction reported (Form 4)
- 2026-06-17 — Insider transaction reported (Form 4)
- 2026-06-16 — Current report (8-K) filed
- 2026-06-09 — Insider transaction reported (Form 4)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, Kyntra Bio Inc has 32 institutional holders and institutional ownership of 25.6%.
Insider activity
Insiders reported 11 transactions (3 buys, 0 sells) across 3 reporting insiders, with a net reported value of $153.2K.
Data flags from SEC filings
Related companies
BioXcel Therapeutics Inc (BTAI) · Koninklijke Philips NV (PHG) · NEUPHORIA THERAPEUTICS IN (NEUP) · CERVOMED INC (CRVO) · TEVOGEN BIO HOLDINGS INC (TVGN) · Lite Strategy Inc (LITS)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-17.